Arrowhead has not initiated research coverage on Diagnos Inc. yet.

About
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, text and traditional data mining. DIAGNOS has developed its own Artificial Intelligence (“AI”) technologies, CARA and FLAIRE. FLAIRE is a powerful AI engine that...
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, text and traditional data mining. DIAGNOS has developed its own Artificial Intelligence (“AI”) technologies, CARA and FLAIRE. FLAIRE is a powerful AI engine that provides the capability of analyzing large and complex data sets. Using Deep Learning methodology combined with our own proprietary algorithms we can deploy rapidly new solutions to the healthcare market Additional information on DIAGNOS is available at www.diagnos.ca and www.sedar.com.
  • 11
    Dec
    17
    Company Presentation
    Diagnos Investor Presentation December 2017
  • 6
    Dec
    17
    News Release
    DIAGNOS Receives Support from Export Development Canada (EDC) for the Issuance of a Performance Bond for the ISSSTE Contract
  • 29
    Nov
    17
    News Release
    DIAGNOS Hires Investor Relation Firm Arrowhead Business and Investment Decisions, LLC and Grants Stock Options
  • 22
    Nov
    17
    News Release
    DIAGNOS Announces a Second Contract for Its Cardio Platform with a Multinational Pharmaceutical Company and the Resignation of a Director
  • 9
    Nov
    17
    News Release
    DIAGNOS Announces New Project with Cardiology Department of the Centre National de Médecine du Sport C.N.M.S Hospital located in Alger, Algeria, before product launch
  • 24
    Oct
    17
    News Release
    DIAGNOS Announces a One-Year Agreement in North Africa with a Major Pharmaceutical Company after Successful Pilot
  • 17
    Oct
    17
    News Release
    DIAGNOS Announces a New Partner in Cambodia, Garuda Health Services
  • 16
    Oct
    17
    News Release
    DIAGNOS Announces Closing of a Private Placement
  • 26
    Sep
    17
    News Release
    DIAGNOS Announces DTC Eligibility of its Common Shares in the US
  • 19
    Sep
    17
    News Release
    DIAGNOS Provides Timelines on Cardiovascular Disease (CVD) Prevention Test Development and Commercialization Plans
  • 17
    Sep
    17
    Corporate Update
    Press Coverage: Journal de Montréal - Détecter les maladies du cœur par une photo
  • 28
    Aug
    17
    News Release
    DIAGNOS Announces Restatement of March 31, 2017 Financial Statements which Resulted in a Decrease in Expenses of $2,491,096
  • 22
    Aug
    17
    News Release
    DIAGNOS Announces 2 screening clinics with Al Kahhal Medical Complex in the Kingdom of Saudi Arabia
  • 14
    Aug
    17
    News Release
    DIAGNOS Announces Results from the Annual Meeting of Shareholders, Appointments of new Chairman and new Chief Medical Officer and Stock Options Grant
  • 17
    Jul
    17
    News Release
    DIAGNOS signs new contract valued at $ 4.16 Million USD (5.26 Million CAD) with the Government of Mexico at ISSSTE to screen and monitor 320,000 diabetics in 2017 further to a successful pilot program
  • 5
    Jul
    17
    News Release
    DIAGNOS Announces Successful Pilot at Chaparral Medical Group in California and a 3 Year Contract with the Opening of a Second Eye Screening Clinic
  • 27
    Jun
    17
    News Release
    DIAGNOS Receives Approval for Trading on the OTCQB Venture Market
  • 31
    May
    17
    News Release
    DIAGNOS Announces its New Mission in Healthcare after its Divestiture from the Mining Industry
  • 26
    May
    17
    Corporate Update
    Press Coverage: The Future Looks Brighter For Patients With Diabetes – Personal Health News
  • 5
    Dec
    16
    Corporate Update
    Press Coverage: A minor could save millions from blindness, LIFE
  • 28
    Nov
    16
    Corporate Update
    Diagnos Q1-2018 MD & A
  • 28
    Nov
    16
    Corporate Update
    Diagnos Q1-2018 Financial Statements